Scientists at The Scripps Research Institute have devised a new antibiotic based on vancomycin that is powerfully effective against vancomycin-resistant strains of MRSA and other disease-causing bacteria. The new vancomycin analog appears to have not one but two distinct mechanisms of anti-microbial action, against which bacteria probably cannot evolve resistance quickly.
Malaria threatens more than 40% of the world’s population and kills up to 1.2 million people worldwide each year. Many of these deaths happen in Sub-Saharan Africa in children under the age of five and pregnant woman. The estimates for clinical infection is somewhere between 300 to 500 million people each year, worldwide.
Gilead Sciences has reached a deal with several generic drugmakers to produce a cheaper version of its popular, $1,000-per-pill hepatitis C drug Sovaldi for use in developing countries. Gilead said that the India-based companies will make a generic version of Sovaldi, also known as sofosbuvir, and another investigational drug for distribution in 91 countries.
Doctors in many U.S. hospitals are unnecessarily prescribing multiple antibiotics for several days when just one would do the job, a new study suggests. Health officials have sounded alarms that overuse of antibiotics is helping to breed dangerous bacteria that are increasingly resistant to treatment. Much of the attention has been on doctor offices that wrongly prescribe bacteria-targeting antibiotics for illnesses caused by viruses.
U.S. regulators have approved the first drug in a new class of cancer medicines that work by stimulating the immune system, a Merck drug developed for treating deadly skin cancer. The Food and Drug Administration says it has granted accelerated approval to Merck's Keytruda, for treating melanoma that's spread or can't be surgically removed, in patients previously treated with another drug.
Eli Lilly and Co. plans to seek approval early next year for a new insulin it developed after the diabetes treatment fared better than the competition in two late-stage clinical studies. The Indianapolis drugmaker said Thursday peglispro produced statistically significant lower blood sugar levels in patients when compared to people who took the Sanofi insulin Lantus in two late-stage studies of people with type 1 diabetes.
A self-assembling nanoparticle designed by a Univ. of Connecticut (UConn) professor is the key component of a potent new malaria vaccine that is showing promise in early tests. For years, scientists trying to develop a malaria vaccine have been stymied by the malaria parasite’s ability to transform itself and “hide” in the liver and red blood cells of an infected person to avoid detection by the immune system.
An experimental Ebola drug healed all 18 monkeys infected with the deadly virus in a study, boosting hopes that the treatment might help fight the outbreak raging through West Africa. Scientists gave the drug, called ZMapp, three to five days after infecting the monkeys in the laboratory. Most were showing symptoms by then, and all completely recovered.
A unique method for delivering compounds that could positively impact the global battle against HIV and AIDS may be possible, thanks to researchers in Penn State's College of Agricultural Sciences. A semi-soft vaginal suppository made from the seaweed-derived food ingredient carrageenan and loaded with the antiviral drug Tenofovir provides a woman-initiated, drug delivery vehicle that can protect against the spread of STIs.
A fortuitous collaboration at Rice Univ. has led to the total synthesis of a recently discovered natural antibiotic. The laboratory recreation of a fungus-derived antibiotic, viridicatumtoxin B, may someday help bolster the fight against bacteria that evolve resistance to treatments in hospitals and clinics around the world.
Federal researchers next week will start testing humans with an experimental vaccine to prevent the deadly Ebola virus. The National Institutes of Health announced Thursday that it is launching the safety trial on a vaccine developed by the agency's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline.
Like a protective tent over a colony of harmful bacteria, biofilms make the treatment of skin infections especially difficult. Microorganisms protected in a biofilm pose a significant health risk due to their antibiotic resistance and recalcitrance to treatment, and biofilm-protected bacteria account for 80% of total bacterial infections in humans and are 50 to 1,000 times more resistant to antibiotics than simpler bacterial infections.
There’s a certain type of biomolecule built like a nano-Christmas tree. Called a glycoconjugate, it’s many branches are bedecked with sugary ornaments. It’s those ornaments that get all the glory. That’s because, according to conventional wisdom, the glycoconjugate’s lowly “tree” basically holds the sugars in place as they do the important work of reacting with other molecules.
Swiss pharmaceutical company Roche said Sunday it has reached an $8.3 billion deal to buy InterMune Inc., a California-based developer of treatments for lung diseases. The companies have reached an agreement under which Roche will acquire InterMune in an all-cash transaction, paying $74.00 per InterMune share, Roche said.
A multidisciplinary team of scientists from the Univ. of California, Los Angeles and Stanford Univ. has used a naturally occurring nanoparticle called a vault to create a novel drug delivery system that could lead to advances in the treatment of cancer and HIV. Their findings could lead to cancer treatments that are more effective with smaller doses and to therapies that could potentially eradicate the HIV virus.
As one of few Ebola survivors with medical expertise, Dr. Kent Brantly seems keenly aware of the position his painful experience has put him in. He hasn't spoken yet about his plans, but spent much of his first public appearance pleading for help for countries still struggling with the virus.
MDR-TB is a growing problem, estimated to kill 170,000 people annually and projected to infect more than two million people between 2011 and 2015. Janssen Research & Development LLC’s bedaquiline represents a significant scientific and public health advancement in the treatment of MDR-TB, as the first available medicine developed specifically for pulmonary MDR-TB treatment.
New research suggests a one-two punch could help battle polio in some of the world's most remote and strife-torn regions: Giving a single vaccine shot to children who've already swallowed drops of an oral polio vaccine greatly boosted their immunity. The World Health Organization officials said the combination strategy already is starting to be used in mass vaccination campaigns in some hard-hit areas.
Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease. The Indianapolis-based company announced initial results from the research on Thursday and said it plans to submit the drug, ixekizumab, to regulators in the first half of next year.
As anyone who has bitten into a chili pepper knows, its burning spiciness—though irresistible to some—is intolerable to others. Scientists exploring the chili pepper’s effect are using their findings to develop a new drug candidate for many kinds of pain, which can be caused by inflammation or other problems. They reported their progress on the compound, which is being tested in clinical trials, in the Journal of Medicinal Chemistry.
Texas researchers are reporting that an experimental drug saved monkeys from a virus closely related to Ebola even after symptoms began. The drug targets a strain of Marburg virus that is even more lethal than the Ebola currently ravaging West Africa. Both viruses take time to multiply in the body before symptoms appear, and few studies have explored how late treatment might be effective.
Two Northwestern Univ. scientists have identified a biomarker strongly associated with basal-like breast cancer, a highly aggressive carcinoma that is resistant to many types of chemotherapy. The biomarker, a protein called STAT3, provides a smart target for new therapeutics designed to treat this often deadly cancer.
British drugmaker AstraZeneca says the U.S. Dept. of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action. The company announced in October 2013 that federal officials were looking into the 18,000-patient study, which began in 2009.
Scientists are racing to begin the first human safety tests of two experimental Ebola vaccines, but it won't be easy to prove that the shots and other potential treatments in the pipeline really work. There are no proven drugs or vaccines for Ebola, a disease so rare that it's been hard to attract investments in countermeasures. But the current outbreak in West Africa is fueling new efforts to speed Ebola vaccine and drug development.
A new technique has demonstrated for the first time that the size of molecules penetrating the blood-brain barrier can be controlled using acoustic pressure. The innovative ultrasound approach uses acoustic pressure to let molecules through, and may help treatment for central nervous system diseases like Parkinson’s and Alzheimer’s.